GlassScriptPhysician profile
Michael D Kuhn
NPI 1659726362
$25,113.49
in general payments reported to CMS, 2019-2025
50 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $1,561 · 2021: $1,556 · 2022: $1,953 · 2023: $1,676 · 2024: $1,874 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $6,040 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,806 · Education: $77.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,000.00 |
| Food and Beverage | $6,040.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,805.65 |
| Education | $77.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $13,805.65 | 2025 | Maci |
| Pfizer INC. | $1,247.83 | 2019-2025 | |
| Viiv Healthcare Company | $1,219.38 | 2020-2025 | Dovato, Rukobia |
| Abbvie INC. | $1,122.89 | 2021-2025 | |
| Novo Nordisk INC | $1,086.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,049.68 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $888.25 | 2020-2025 | Descovy, Yeztugo |
| Astrazeneca Pharmaceuticals LP | $370.74 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $359.48 | 2020-2025 | |
| Janssen Biotech, INC. | $358.31 | 2021-2023 | Symtuza |
| Lilly USA, LLC | $277.83 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $266.79 | 2020-2025 | Veozah, Cresemba |
| Madrigal Pharmaceuticals | $228.07 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $200.99 | 2021-2025 | Gardasil 9, Capvaxive, Zerbaxa |
| Amarin Pharma, INC. | $190.10 | 2019-2021 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $184.89 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.13 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $158.70 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.65 | 2020-2025 | Xifaxan, Trulance |
| Insmed, INC. | $140.46 | 2021-2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $138.46 | 2020-2024 | Xarelto |
| Abbott Laboratories | $137.85 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $132.79 | 2023-2025 | Repatha, Otezla, Prolia |
| Allergan, INC. | $112.75 | 2020 | |
| Paratek Pharmaceuticals, INC. | $90.26 | 2020-2024 | Nuzyra |
| Janssen Products, LP | $89.99 | 2022 | |
| Shionogi INC | $87.32 | 2022-2025 | Fetroja |
| Ferring Pharmaceuticals INC. | $82.27 | 2022-2024 | Rebyota |
| Theratechnologies INC. | $77.26 | 2020-2024 | Egrifta, Trogarzo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.08 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $65.83 | 2023-2025 | |
| Phadia US INC. | $64.84 | 2020-2022 | |
| Csl Behring | $54.45 | 2023 | Hizentra |
| Alk-Abello, INC | $50.33 | 2024 | Grastek, Odactra, Ragwitek |
| Otsuka America Pharmaceutical, INC. | $46.35 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $45.26 | 2023-2024 | Belbuca, Xtampza |
| Axsome Therapeutics, INC. | $42.71 | 2023-2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $38.26 | 2024 | |
| Seqirus USA INC | $26.03 | 2025 | Flucelvax, Fluad |
| Insulet Corporation | $24.96 | 2025 | Omnipod |
| Nabriva Therapeutics, Plc | $24.46 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $18.29 | 2024 | Kristalose |
| Grifols USA, LLC | $17.78 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.20 | 2022 | |
| Genentech USA, INC. | $15.60 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.48 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.90 | 2025 | Voquezna |
| Corium, LLC | $11.40 | 2025 | Azstarys |
| Inogen, INC. | $8.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.